References
- Deepak P, Kumar TN. Duloxetine-Pharmacological aspects. Int J Biol Med Res 2011;2:589–592.
- FDA News Release. FDA clears cymbalta to treat chronic musculoskeletal pain. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm232708.htm [Accessed on June 28, 2012].
- Collado Serra A, Rubio-Briones J, Puyol Payás M, Iborra Juan I, Ramón-Borja JC, Solsona Narbón E. Postprostatectomy established stress urinary incontinence treated with duloxetine. Urology 2011;78:261–266.
- Safer DL, Arnow KD. Suprathreshold duloxetine for treatment- resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. Innov Clin Neurosci 2012;9:13–16.
- Christensen RC, Averbuch RN. The use of duloxetine in chronic bulimia nervosa: a case report. Psychiatry (Edgmont) 2009;6:27–28.
- Gahimer J, Wernicke J, Yalcin I, Ossanna MJ, Wulster-Radcliffe M, Viktrup L. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175–184.
- Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005;4:987–993.
- American Association of Poison Control Centers (AAPCC) NPDS Annual Report Terminology. Available at:] http://www.aapcc.org/dnn/NewsandEvents/NewsMediaResources/NPDSAnnualReportTerminology.aspx [Accessed on March 7, 2012].
- Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, . Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25: 871–880.
- Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005;11:1475–1493.
- Pfizer Pharmaceuticals. Effexor Data Sheet. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=99 [Accessed on June 28, 2012].
- Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 2009;67:572–576.
- Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369–374.
- Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, . Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:315–332.
- Menchetti M, Gozzi BF, Saracino MF, Mercolini L, Petio C, Raggi MA. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 2009;10:385–389.
- Paulzen M, Hiemke C, Grunder G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol 2009;12:1431–1432.
- Kruithof MK, Bruins NA, van Roon EN. Coma after overdose with duloxetine. Ann Pharmacother 2011;45:e5.
- Melani F, Rosati E, Chiocchetti B, Muscas GC. Antidepressant- associated myoclonic status in a patient with symptomatic generalized epilepsy: does risk occur with therapeutic doses? Epilepsy Behav 2009;14:681–683.
- Qadir A, Naveed H. Duloxetine withdrawal seizure. Psychiatry (Edgmont) 2006;3:10.
- Food and Drug Administration (FDA). Highlights of Prescribing Information, Cymbalta Delayed-Release Capsules for Oral Use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021427s039lbl.pdf [Accessed on June 28, 2012].
- Pellicciari A, Balzarro B, Scaramelli A, Porcelli S, Serretti A, De Ronchi D. Generalized tonic-clonic seizure secondary to duloxetine poisoning: A short report with favorable outcome. Neurotoxicology 2012;33:189–190.
- Cymbalta(duloxetine) Package insert. Available at: http://pi.lilly.com/us/cymbalta-pi.pdf [Accessed on March 7, 2012].
- Prakash A, Lobo E, Kratochvil CJ, Tamura RN, Pangallo BA, Bullok KE, . An open-label safety and pharmacokinetics study of duloxetine in pediatric patients with major depression. J Child Adolesc Psychopharmacol 2012;22:48–55.